Eagle Asset Management Inc. trimmed its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 29.3% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 217,338 shares of the medical equipment provider's stock after selling 90,246 shares during the quarter. Eagle Asset Management Inc. owned about 0.31% of Lantheus worth $23,853,000 at the end of the most recent quarter.
Several other hedge funds have also recently bought and sold shares of the business. Signaturefd LLC increased its position in Lantheus by 40.5% during the third quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider's stock worth $35,000 after buying an additional 92 shares during the last quarter. Silverberg Bernstein Capital Management LLC increased its position in Lantheus by 0.4% during the second quarter. Silverberg Bernstein Capital Management LLC now owns 22,843 shares of the medical equipment provider's stock worth $1,834,000 after buying an additional 100 shares during the last quarter. UMB Bank n.a. increased its position in Lantheus by 42.1% during the third quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider's stock worth $47,000 after buying an additional 126 shares during the last quarter. GAMMA Investing LLC increased its position in Lantheus by 45.5% during the third quarter. GAMMA Investing LLC now owns 467 shares of the medical equipment provider's stock worth $51,000 after buying an additional 146 shares during the last quarter. Finally, Moody National Bank Trust Division increased its position in Lantheus by 1.1% during the second quarter. Moody National Bank Trust Division now owns 14,984 shares of the medical equipment provider's stock worth $1,203,000 after buying an additional 162 shares during the last quarter. 99.06% of the stock is owned by institutional investors and hedge funds.
Shares of LNTH opened at $90.52 on Friday. The stock has a market cap of $6.29 billion, a price-to-earnings ratio of 15.06 and a beta of 0.51. Lantheus Holdings, Inc. has a 12 month low of $50.20 and a 12 month high of $126.89. The company has a 50-day moving average price of $103.43 and a two-hundred day moving average price of $96.53.
LNTH has been the topic of several research analyst reports. Truist Financial reaffirmed a "buy" rating and issued a $120.00 price target (down from $135.00) on shares of Lantheus in a research report on Friday, November 8th. Redburn Atlantic initiated coverage on Lantheus in a research report on Tuesday, September 3rd. They issued a "buy" rating and a $175.00 price target on the stock. StockNews.com downgraded Lantheus from a "buy" rating to a "hold" rating in a research report on Thursday. Finally, JMP Securities decreased their target price on Lantheus from $125.00 to $112.00 and set a "market outperform" rating on the stock in a research report on Thursday, November 7th. Two equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $122.50.
Get Our Latest Research Report on Lantheus
Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Lantheus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lantheus wasn't on the list.
While Lantheus currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.